CC-220 functions as an IKZF1/3 degrader for MM; ARV-471 degrades ER in breast cancer; HJM-561 targets EGFR for lung cancer; DT2216 targets BCL-XL in leukemia; DD-03-171 acts on BTK for lymphoma; ARV-776 is an AR degrader for prostate cancer; MS-6105 degrades lactate dehydrogenase in pancreatic cancer; CFT8634 targets BRD9 in synovial sarcoma. This evidence concerns the gene AR and prostate carcinoma.